P.A.W. Capital’s Lipocine LPCN Stock Holding History

P.A.W. Capital’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-5,882	Closed	-$397K	–	65
2017 Q3	$397K	Buy	+5,882	New	+$425K	0.42%	70
2015 Q3	–	Sell	-2,059	Closed	-$300K	–	66
2015 Q2	$300K	Buy	+2,059	New	+$256K	0.3%	65

Other funds holding LPCN

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DAM

DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return

P.A.W. Capital's LPCN Position: Q4 2017 in Review

P.A.W. Capital sold out of Lipocine (LPCN) in Q4 2017, closing a stake of 5,882 shares — an estimated $397K sold.

P.A.W. Capital first reported a position in LPCN in Q2 2015 and held it in 2 quarters. The position peaked at $397K in Q3 2017. 39 funds tracked by Wall St. Rank hold LPCN as of Q4 2017.

P.A.W. Capital reported no remaining Lipocine position as of Q4 2017 after selling out during the quarter.
P.A.W. Capital sold 5,882 Lipocine shares in Q4 2017, an estimated $397K.
P.A.W. Capital first reported a position in Lipocine in Q2 2015 and held it in 2 quarters.
P.A.W. Capital's Lipocine position peaked at $397K in Q3 2017.
39 funds tracked by Wall St. Rank held Lipocine as of Q4 2017.

Based on P.A.W. Capital's 13F filing for Q4 2017, filed 31 Jan 2018.